Braidwell LP Sells 350,200 Shares of X4 Pharmaceuticals, Inc. $XFOR

Key Points

• Braidwell LP reduced its X4 Pharmaceuticals stake by 10.7% in the second quarter, selling 350,200 shares and retaining 2.92 million shares valued at approximately $13.6 million. Institutional investors collectively own 72.03% of the company.
• X4 reported quarterly revenue of $8.81 million and an adjusted loss of $0.13 per share, beating analysts’ expectations, though the company remains unprofitable with a negative net margin of 568.8%.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an average price target of $11.25 versus the stock’s reported price of $4.04; however, company insiders have sold 80,555 shares worth $356,126 over the past 90 days.

Braidwell LP lessened its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) by 10.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,922,754 shares of the company's stock after selling 350,200 shares during the period. Braidwell LP owned about 2.95% of X4 Pharmaceuticals worth $13,649,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Empery Asset Management LP purchased a new position in X4 Pharmaceuticals in the fourth quarter valued at about $35,804,000. Bain Capital Life Sciences Investors LLC increased its stake in shares of X4 Pharmaceuticals by 227.0% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company's stock worth $31,870,000 after purchasing an additional 5,530,866 shares during the last quarter. Perceptive Advisors LLC raised its holdings in shares of X4 Pharmaceuticals by 6.7% in the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company's stock worth $27,826,000 after purchasing an additional 423,196 shares during the period. Kalehua Capital Management LLC bought a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth approximately $14,891,000. Finally, Rosalind Advisors Inc. lifted its stake in X4 Pharmaceuticals by 68.7% in the fourth quarter. Rosalind Advisors Inc. now owns 2,605,920 shares of the company's stock valued at $10,424,000 after purchasing an additional 1,061,313 shares during the last quarter. Institutional investors own 72.03% of the company's stock.

X4 Pharmaceuticals Stock Performance

NASDAQ XFOR opened at $4.04 on Thursday. The company's 50 day moving average is $4.08 and its 200-day moving average is $4.00. X4 Pharmaceuticals, Inc. has a 12-month low of $2.80 and a 12-month high of $4.83. The company has a quick ratio of 11.02, a current ratio of 11.30 and a debt-to-equity ratio of 0.49. The firm has a market cap of $400.57 million, a P/E ratio of -3.37 and a beta of 0.39.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. The company had revenue of $8.81 million for the quarter, compared to analysts' expectations of $2.42 million. Sell-side analysts predict that X4 Pharmaceuticals, Inc. will post -0.71 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on XFOR. Leerink Partners started coverage on X4 Pharmaceuticals in a report on Tuesday, June 2nd. They set an "outperform" rating and a $12.00 price objective for the company. Weiss Ratings upgraded X4 Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 25th. Finally, Wells Fargo & Company began coverage on X4 Pharmaceuticals in a research report on Friday, July 10th. They set an "overweight" rating and a $11.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $11.25.

Insiders Place Their Bets

In other news, Chairman Adam R. Craig sold 47,436 shares of X4 Pharmaceuticals stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $210,615.84. Following the completion of the transaction, the chairman directly owned 328,651 shares in the company, valued at approximately $1,459,210.44. The trade was a 12.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO David Kirske sold 8,543 shares of the business's stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total value of $36,393.18. Following the sale, the chief financial officer owned 167,750 shares in the company, valued at approximately $714,615. The trade was a 4.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 80,555 shares of company stock worth $356,126 over the last 90 days. Corporate insiders own 1.13% of the company's stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company's lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström's macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.